Adcock Ingram Delisting After Natco Acquisition

Original Article by Jacqueline Mackenzie | Business Day | 27 October 2025

Adcock Ingram delisting from the JSE is confirmed for November 11. Learn about the impact of the Natco Pharma acquisition.

Adcock Ingram delisting from the JSE is confirmed for November 11. Learn about the impact of the Natco Pharma acquisition.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here

More Posts

Older Adults With HIV Set To Double By 2040

Older adults with HIV will nearly double by 2040. South Africa faces one of the sharpest rises, straining health systems.

Read more...

Rosebank Health Village Expands Growthpoint Portfolio

Rosebank Health Village, a R100 million Growthpoint and Epione development, brings specialists, diagnostics and day surgery together.

Read more...

Global HIV Funding Cuts Put AIDS Progress At Risk

Global HIV funding cuts pushed financing to a 20-year low in 2025, threatening prevention, research and the goal of ending AIDS by 2030.

Read more...